A Study of Bitopertin (RO4917838) in Adults With Non-Transfusion-Dependent (NTD) Beta-Thalassemia

• Status: Completed
• Trial end date: 2018-06-29
• Target enrollment: 0
• Participant gender: All

Summary

This proof-of-mechanism study is being performed to investigate the safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of multiple oral doses of bitopertin in adults with NTD beta-thalassemia.

This study consists of two parts:

Part 1 - The main study - 16 weeks in total: Participants will undergo a 6-week dose-escalation period followed by 10 weeks of treatment at the attained target dose.

Part 2 - Open Label Extension (OLE) - up to an additional 12 months. Participants will be given the option to enroll into the OLE once the 16-week treatment of Part 1 has been completed. Participants who decide not to enroll in the OLE, at the end of Part 1 will enter a 6-week follow-up period.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hoffmann-La Roche

Criteria

Inclusion Criteria:

• Confirmed diagnosis of beta-thalassemia

• Clinically defined non-transfusion-dependent anemia (Part 1 only), defined as Hb concentrations >7.5 grams per deciliter (g/dL) and <9.5 g/dL, less than or equal to 4 transfusions of red blood cell units within 1 year prior to study enrollment, and no transfusion within 12 weeks prior to study enrollment

• Completion of 16 weeks of treatment with bitopertin in Part 1 of this study with more than 80% compliance from expected use of study medication (based on patient diary and study drug accountability; Part 2 only)

• A favorable benefit-risk ratio from treatment with bitopertin as assessed by the Investigator (Part 2 only)

Exclusion Criteria:

• Any history of gene therapy

• History of hemolytic anemia except for beta-thalassemia

• Severe symptomatic splenomegaly and/or hepatomegaly with hypersplenism (Part 1 only)

• Any use of an erythropoiesis-stimulating agent within 24 weeks prior to enrollment.

• Initiation of iron chelation therapy or hydroxyurea within 24 weeks prior to enrollment (Part 1 only)

• Depression, treatment with anti-depressants, or other psychiatric illnesses and/or drug abuse

• Clinically significant/uncontrolled comorbid disease

• Pregnant or breastfeeding females

• Use of cytochrome P450 (CYP) 3A4 inhibitors within 2 weeks or CYP3A4 inducers within 4 weeks prior to study drug

• Active hepatitis B or C or known positive human immunodeficiency virus (HIV) test result

• Diagnosis of cancer within previous 5 years unless treatment has resulted in complete freedom from disease for at least 2 years

• Any major illness within 1 month or febrile illness within 1 week prior to study drug

• Pulmonary hypertension requiring oxygen therapy (Part 1 only)